While most of the SETD2 mutations in our cohort are likely inactivating because they are frameshift or nonsense mutations (5/6), one patient’s tumor contained a missense mutation (R1592P in patient m11) that is predicted as ‘probably damaging’ by Polyphen-2. The gene discussed is SETD2; the disease is neoplasm.